Currently, there are 131.69M common shares owned by the public and among those 106.65M shares have been available to trade.
Insiders at the company have transacted a total of 25 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 22 of these insider trades were purchases, accounting for 643,955 shares. Insider sales of the common stock occurred on 3 occasions, with total insider shares sold totaling 76,324 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 8.62, up 63.60%. The company’s stock has a 5-day price change of 52.55% and 69.57% over the past three months. MRVI shares are trading 27.63% year to date (YTD), with the 12-month market performance down to -39.55% lower. It has a 12-month low price of $4.52 and touched a high of $16.90 over the same period. MRVI has an average intraday trading volume of 2.06 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 50.73%, 38.20%, and -8.08% respectively.
Institutional ownership of Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) shares accounts for 86.15% of the company’s 131.69M shares outstanding.
It has a market capitalization of $1.11B and a beta (3y monthly) value of -0.23. The earnings-per-share (ttm) stands at -$0.90. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.80% over the week and 7.12% over the month.
Analysts forecast that Maravai LifeSciences Holdings Inc (MRVI) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0.1 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.02 while analysts give the company a high EPS estimate of $0.03. Comparatively, EPS for the current quarter was $0.03 a year ago. Earnings per share for the fiscal year are expected to decrease by -153.88%, and 383.98% over the next financial year.
Looking at the support for the MRVI, a number of firms have released research notes about the stock. BofA Securities stated their Buy rating for the stock in a research note on December 12, 2023, with the firm’s price target at $10-$8. UBS on their part issued Neutral rating on January 05, 2023.
